Pharmaceuticals

Thyroid Cancer Drugs Industry Insights: Market Forecast to 2029

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Thyroid Cancer Drugs Market Size Likely To Evolve From 2025 Through 2034?

The market size for thyroid cancer drugs has experienced rapid expansion in recent years. This market is set to grow from $1.16 billion in 2024 to $1.32 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.6%. The expansion observed in the historic period is largely attributable to factors such as the increasing incidence of thyroid cancer, breakthroughs in medical research, a supportive regulatory environment, and rising healthcare expenditure.

The market for thyroid cancer drugs is projected to experience swift expansion in the coming years, set to reach $2.12 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.6%. This anticipated growth during the forecast period is attributable to factors such as the rising incidence of the disease, an aging global population, breakthroughs in precision medicine, improvements in healthcare infrastructure, and increased awareness leading to earlier detection. Key trends anticipated during this period encompass personalized medicine, the evolution of targeted therapies and immunotherapies, ongoing clinical trials and a robust drug pipeline, the adoption of combination therapies, biomarker-driven treatment approaches, and the increasing use of telemedicine and remote patient monitoring.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=2601&type=smp

Which Drivers Are Supporting Growth Of The Thyroid Cancer Drugs Market?

The escalating frequency of thyroid cancer occurrences, particularly affecting women, is a primary impetus for the thyroid cancer drugs market. For instance, in 2022, The American Cancer Society, a US-based organization, estimated around 43,800 new cases of thyroid cancer in the United States, with 31,940 cases being among women and 11,860 among men. Additionally, 2,230 deaths resulted from thyroid cancer, including 1,070 men and 1,160 women. Thus, the increasing prevalence of thyroid cancer, specifically in women, is fueling the expansion of the thyroid cancer industry.

What Are The Major Segments Identified In The Thyroid Cancer Drugs Market?

The thyroid cancer drugs market covered in this report is segmented –

1) By Drug Type: Ipilimumab, Cabozantinib-S-Malate, Caprelsa (Vandetanib), Doxorubicin Hydrochloride, Lenvatinib Mesylate, Nivolumab, Vandetanib, Other Drug Types

2) By Type: Radioiodine Ablation, Thyroid Stimulating Hormone (THS) Suppression, Chemotherapy, Targeted Multikinase Therapy, Other Types

3) By End Users: Hospitals, Oncology Clinics, Research Organizations, Other End-Users

Subsegments:

1) By Ipilimumab: Monotherapy Ipilimumab, Combination Therapy With Ipilimumab

2) By Cabozantinib-S-Malate: Single-Agent Cabozantinib, Combination Therapy With Cabozantinib

3) By Caprelsa (Vandetanib): Vandetanib For Medullary Thyroid Cancer (MTC), Combination Therapy With Vandetanib

4) By Doxorubicin Hydrochloride: Doxorubicin For Chemotherapy, Liposomal Doxorubicin

5) By Lenvatinib Mesylate: Lenvatinib For Differentiated Thyroid Cancer (DTC), Combination Therapy With Lenvatinib

6) By Nivolumab: Monotherapy Nivolumab, Combination Therapy With Nivolumab

7) By Vandetanib: Single-Agent Vandetanib, Combination Therapy With Vandetanib

8) By Other Drug Types: Sorafenib, Everolimus, Pembrolizumab

What Are The Major Trends Driving The Growth Of The Thyroid Cancer Drugs Market?

Combination medications are seeing increased application in treating thyroid cancer, owing to their superior effectiveness and role in hindering cancer progression. A combination drug is defined as having two or more active pharmaceutical ingredients (APIs) integrated into a single dosage form. These therapeutics are effective in minimizing the onset of drug resistance and suppressing the proliferation of cancer cells. For example, the FDA granted approval for the combined use of dabrafenib (Tafinlar), which is a BRAF inhibitor, and trametinib (Mekinist), a MEK inhibitor, specifically for the treatment of anaplastic thyroid cancer.

Which Major Firms Are Strengthening Their Position In The Thyroid Cancer Drugs Industry?

Major companies operating in the thyroid cancer drugs market include Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Baxter International Inc., Abbott Laboratories, APP Pharmaceuticals LLC, AstraZeneca PLC, GlaxoSmithKline plc, Exelixis Inc., Novartis AG, Pfizer Inc., Biovista Inc., Vascular Biogenics Ltd., Azaya Therapeutics Inc., Bionomics Limited, Bayer AG, Eisai Co. Ltd., Bio-Path Holdings Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bristol-Myers Squibb Company, Celgene Corporation (a subsidiary of Bristol-Myers Squibb Company), Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Hikma Pharmaceuticals PLC, Ipsen Biopharmaceuticals Inc., Johnson & Johnson, Kyowa Kirin Co. Ltd., Merck & Co. Inc., Sanofi S.A., Amgen Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Gilead Sciences Inc., Grifols S.A., Jazz Pharmaceuticals plc, Mallinckrodt Pharmaceuticals (a subsidiary of Specialty Generics Holdings), Medtronic plc, Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/thyroid-cancer-drugs-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Thyroid Cancer Drugs Market?

North America was the largest region in the thyroid cancer drugs market in 20242. Middle East is expected to be the fastest-growing region in the thyroid cancer drugs market during the forecast period. The regions covered in the thyroid cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request A Customized Version Of The Thyroid Cancer Drugs Market Report:

https://www.thebusinessresearchcompany.com/customise?id=2601&type=smp

Browse Through More Reports Similar to the Global Thyroid Cancer Drugs Market 2025, By The Business Research Company

Diuretics Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report

Genito Urinary Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report

Dermatology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dermatology-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795